A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Bevacizumab (Primary) ; Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms IOLANTHE
Most Recent Events
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 10 Nov 2023 New trial record